Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1

Conditions

Lymphoma, Follicular 2Renal Insufficiency 1Neoplasms 1Hypertension 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT03872778 2026-04-30

NeoRay

Advanced Accelerator Applications

Phase 1/2 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT06236061 2026-01-13

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Novartis

Phase 3 Completed
718 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

NCT01569815 2015-10-19

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Novartis

Phase 1 Completed
32 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡